JNJJohnson & Johnson

Form: 8-K (Items 2.02, 9.01) | Filed with the SEC on: October 13, 2026 | Price: $250.97 | Today's Change: -4.84%

---

What Happened

Johnson & Johnson filed an 8-K with the SEC on October 13, 2026, disclosing its financial results for the second quarter of fiscal year 2026 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits). Revenue from contracts with customers (excluding assessed tax) came in at $45.636 billion for Q2 FY2026, while net income reached $16.536 billion for the same period. Basic earnings per share were $6.87 and diluted earnings per share were $6.82, reflecting the company's substantial profitability during the quarter.

Why It Matters

The headline figures represent a significant absolute dollar scale of business for one of the world's largest healthcare companies. With diluted EPS of $6.82 and net income of approximately $16.5 billion in a single quarter, these results underscore the underlying earnings power of J&J's diversified healthcare portfolio. However, the stock's sharp decline of -4.84% on the day of the report suggests the market's reaction was notably negative — indicating that investors may have found the results, guidance, or accompanying commentary to fall short of prevailing expectations, despite the substantial absolute profit levels reported. Investors should weigh the absolute profitability figures against whatever forward-looking context accompanied the filing.

Analysis

The immediate market reaction — a decline of nearly 5% — is the most telling signal here. For a mega-cap, blue-chip name like Johnson & Johnson, a move of that magnitude on an earnings day typically reflects a meaningful miss versus consensus estimates, a downward revision to full-year guidance, or concerning commentary around one or more key business segments. The Q2 FY2026 revenue figure of $45.636 billion and net income of $16.536 billion are large in absolute terms, but context relative to analyst expectations — which are not available in the structured XBRL data provided — is what drives price discovery on earnings days.

Key items to watch going forward include:

• Guidance updates: Whether management revised full-year revenue or EPS guidance up or down, and by how much.
• Segment performance: How J&J's pharmaceutical and MedTech divisions individually contributed to the headline numbers.
• Legal and litigation developments: Any updates on ongoing talc or other liability matters that may have colored investor sentiment.
• Pipeline commentary: Any shifts in the outlook for key drug approvals or MedTech launches.

The -4.84% move on the filing date warrants close attention to the earnings call transcript and any supplementary materials included in the 9.01 exhibit, as those will contain the granular breakdown and management tone that explain the market's reaction far better than top-line figures alone.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Johnson & Johnson's SEC filing and publicly available market price data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation of any kind. No rating or price target is assigned. Readers should conduct their own due diligence and consult a qualified financial adviser before making any investment decisions.

Source

Filed with the SEC on 2026-10-13. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm